Oryon Cell Therapies emerged from stealth to present early clinical data for an autologous neuron replacement program in Parkinson’s disease and announced fresh funding and leadership moves. The company disclosed Phase Ib/IIa results at AD/PD and confirmed an additional $21 million tranche, bringing total fundraising to date to support continued development. Oryon also appointed industry veteran Ron Cohen as CEO to accelerate development and commercialization plans. The filings and data mark a visible push to commercialize personalized cell therapies for neurodegeneration and to translate neuron replacement concepts into clinical-stage programs.